Silence Therapeutics (NASDAQ:SLN) Releases Quarterly Earnings Results, Misses Estimates By $0.14 EPS

Silence Therapeutics (NASDAQ:SLN) announced its earnings results on Thursday. The company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.14), Zacks reports. Silence Therapeutics had a negative return on equity of 95.93% and a negative net margin of 8,943.86%.The company had revenue of $0.42 million during the quarter, compared to the consensus estimate of $1.26 million.

Silence Therapeutics Stock Performance

SLN stock traded up $0.02 during trading on Friday, hitting $6.97. 326,786 shares of the company’s stock traded hands, compared to its average volume of 422,206. Silence Therapeutics has a 52 week low of $3.56 and a 52 week high of $8.40. The stock has a market capitalization of $329.19 million, a price-to-earnings ratio of -4.38 and a beta of 1.52. The business has a fifty day simple moving average of $6.41 and a 200 day simple moving average of $6.15.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Boothbay Fund Management LLC increased its stake in Silence Therapeutics by 1.0% during the second quarter. Boothbay Fund Management LLC now owns 252,421 shares of the company’s stock worth $1,464,000 after acquiring an additional 2,409 shares during the last quarter. Two Sigma Investments LP boosted its holdings in shares of Silence Therapeutics by 6.6% in the 3rd quarter. Two Sigma Investments LP now owns 63,247 shares of the company’s stock worth $328,000 after purchasing an additional 3,935 shares during the period. ADAR1 Capital Management LLC increased its position in shares of Silence Therapeutics by 26.8% during the 4th quarter. ADAR1 Capital Management LLC now owns 23,643 shares of the company’s stock valued at $144,000 after purchasing an additional 5,000 shares during the last quarter. Bank of Montreal Can raised its holdings in Silence Therapeutics by 4.4% during the 4th quarter. Bank of Montreal Can now owns 160,474 shares of the company’s stock valued at $976,000 after buying an additional 6,692 shares during the period. Finally, XTX Topco Ltd purchased a new stake in Silence Therapeutics during the 4th quarter valued at $71,000. Hedge funds and other institutional investors own 98.73% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. William Blair reiterated an “outperform” rating on shares of Silence Therapeutics in a research report on Monday, March 2nd. Jefferies Financial Group upgraded Silence Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 18th. HC Wainwright reiterated a “buy” rating and set a $75.00 price objective on shares of Silence Therapeutics in a research report on Friday, March 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Silence Therapeutics in a report on Tuesday, April 21st. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $55.00.

About Silence Therapeutics

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.